Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma

Shigeo Shimose, Shunji Koya, Takumi Kawaguchi, Keisuke Hirota, Sachiyo Yoshio, Takashi Niizeki, Hiroo Matsuse, Takuji Torimura

Clin Mol Hepatol. 2021;27(4):616-619. Published online September 13, 2021

DOI: https://doi.org/10.3350/cmh.2021.0258

Original Article

New next-generation microwave thermosphere ablation for small hepatocellular carcinoma

Hideyuki Tamai, Jumpei Okamura

Clin Mol Hepatol. 2021;27(4):564-574. Published online August 2, 2021

Cited By 2

DOI: https://doi.org/10.3350/cmh.2021.0136

Editorial

Microwave thermosphere versus radiofrequency ablation for hepatocellular carcinoma: Are we approaching the time to end the debate?

Man-Deuk Kim

Clin Mol Hepatol. 2021;27(4):560-561. Published online September 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0279

Original Article

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Lilian Yan Liang, Hye Won Lee, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip, Yee-Kit Tse, Vicki Wing-Ki Hui, Grace Chung-Yan Lui, Henry Lik-Yuen Chan, Grace Lai-Hung Wong

Clin Mol Hepatol. 2021;27(3):499-509. Published online February 26, 2021

Cited By 1

DOI: https://doi.org/10.3350/cmh.2020.0333

Editorial

Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeAg status?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2021;27(3):448-450. Published online June 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0130

Review

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim

Clin Mol Hepatol. 2021;27(3):402-412. Published online June 23, 2021

Cited By 9

DOI: https://doi.org/10.3350/cmh.2021.0179

Original Article

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma

Ching-Chih Lin, Ta-Wei Liu, Ming-Lun Yeh, Yi-Shan Tsai, Pei-Chien Tsai, Chung-Feng Huang, Jee-Fu Huang, Wan-Long Chuang, Chia-Yen Dai, Ming-Lung Yu

Clin Mol Hepatol. 2021;27(2):313-328. Published online December 14, 2020

Cited By 1

DOI: https://doi.org/10.3350/cmh.2020.0247

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2021;27(2):295-304. Published online December 3, 2020

Cited By 5

DOI: https://doi.org/10.3350/cmh.2020.0216

Review

Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects

Takuji Torimura, Hideki Iwamoto

Clin Mol Hepatol. 2021;27(2):236-245. Published online December 3, 2020

Cited By 9

DOI: https://doi.org/10.3350/cmh.2020.0204

Original Article

Obesity and the risk of primary liver cancer: A systematic review and meta-analysis

Won Sohn, Hyun Woong Lee, Sangheun Lee, Jin Hong Lim, Min Woo Lee, Chan Hyuk Park, Seung Kew Yoon

Clin Mol Hepatol. 2021;27(1):157-174. Published online November 26, 2020

Cited By 13

DOI: https://doi.org/10.3350/cmh.2020.0176

Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study

Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park

Clin Mol Hepatol. 2021;27(1):144-156. Published online December 7, 2020

Cited By 6

DOI: https://doi.org/10.3350/cmh.2020.0095

Editorial

Old hepatitis B virus never dies: It just hides itself within the host genome

Jeong-Hoon Lee

Clin Mol Hepatol. 2021;27(1):107-109. Published online December 23, 2020

Cited By 2

DOI: https://doi.org/10.3350/cmh.2020.0324

Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma

Jun Won Kim, Ik Jae Lee

Clin Mol Hepatol. 2021;27(1):103-106. Published online December 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0297

Metabolic disease as a risk of hepatocellular carcinoma

Naoshi Nishida

Clin Mol Hepatol. 2021;27(1):87-90. Published online December 3, 2020

Cited By 5

DOI: https://doi.org/10.3350/cmh.2020.0302

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Hepatic Hippo signaling inhibits development of hepatocellular carcinoma

Yuchen Liu, Xiaohui Wang, Yingzi Yang

Clin Mol Hepatol. 2020;26(4):742-750. Published online September 28, 2020

Cited By 19

DOI: https://doi.org/10.3350/cmh.2020.0178

Letter to the Editor

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

Jeong Su Park, Soo Han Bae

Clin Mol Hepatol. 2020;26(4):577-578. Published online September 17, 2020

Cited By 1

DOI: https://doi.org/10.3350/cmh.2020.0143

Original Article

Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway

Seulki Lee, Eun Ji Choi, Eun Ju Cho, Yun Bin Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim

Clin Mol Hepatol. 2020;26(4):529-539. Published online August 24, 2020

Cited By 15

DOI: https://doi.org/10.3350/cmh.2019.0056n

Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients

Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik

Clin Mol Hepatol. 2020;26(4):516-528. Published online September 11, 2020

Cited By 17

DOI: https://doi.org/10.3350/cmh.2020.0016

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial

Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee

Clin Mol Hepatol. 2020;26(4):506-515. Published online July 10, 2020

Cited By 20

DOI: https://doi.org/10.3350/cmh.2020.0038

Editorial

Long-term prognosis and management of hepatocellular carcinoma after curative treatment

Naoshi Nishida

Clin Mol Hepatol. 2020;26(4):480-483. Published online September 21, 2020

Cited By 4

DOI: https://doi.org/10.3350/cmh.2020.0208

Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma

Sooyeon Oh, Jooho Lee

Clin Mol Hepatol. 2020;26(4):476-479. Published online October 1, 2020

Cited By 4

DOI: https://doi.org/10.3350/cmh.2020.0192

Original Article

Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir

Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2020;26(3):364-375. Published online May 29, 2020

Cited By 11

DOI: https://doi.org/10.3350/cmh.2020.0012

Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging

Sunyoung Lee, Seung-seob Kim, Dong ryul Chang, Hyerim Kim, Myeong-Jin Kim

Clin Mol Hepatol. 2020;26(3):340-351. Published online June 4, 2020

Cited By 23

DOI: https://doi.org/10.3350/cmh.2020.0004

Editorial

Diagnosis of hepatocellular carcinoma: Which MRI contrast agent? Which diagnostic criteria?

So Yeon Kim

Clin Mol Hepatol. 2020;26(3):309-311. Published online June 15, 2020

Cited By 4

DOI: https://doi.org/10.3350/cmh.2020.0061

Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma

Sojung Han, Do Young Kim

Clin Mol Hepatol. 2020;26(3):305-308. Published online July 1, 2020

Cited By 3

DOI: https://doi.org/10.3350/cmh.2020.0096

Original Article

Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma

Rahul Kumar, Boon-Bee George Goh, Jia-Wen Kam, Pik-Eu Chang, Chee-Kiat Tan

Clin Mol Hepatol. 2020;26(2):196-208. Published online January 9, 2020

Cited By 6

DOI: https://doi.org/10.3350/cmh.2019.0012

Review

Switching to systemic therapy after locoregional treatment failure: Definition and best timing

Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato

Clin Mol Hepatol. 2020;26(2):155-162. Published online January 15, 2020

Cited By 18

DOI: https://doi.org/10.3350/cmh.2019.0021n

Original Article

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti

Clin Mol Hepatol. 2020;26(1):45-53. Published online September 30, 2019

Cited By 9

DOI: https://doi.org/10.3350/cmh.2019.0031

A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea

Jae Seung Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jin Sil Seong, Kwang-Hyub Han, Do Young Kim

Clin Mol Hepatol. 2020;26(1):24-32. Published online May 20, 2019

Cited By 18

DOI: https://doi.org/10.3350/cmh.2018.0065

Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients

Kei Moriya, Tadashi Namisaki, Shinya Sato, Masanori Furukawa, Akitoshi Douhara, Hideto Kawaratani, Kosuke Kaji, Naotaka Shimozato, Yasuhiko Sawada, Soichiro Saikawa, Hiroaki Takaya, Koh Kitagawa, Takemi Akahane, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji

Clin Mol Hepatol. 2019;25(4):381-389. Published online August 13, 2019

Cited By 9

DOI: https://doi.org/10.3350/cmh.2019.0037

1 | 2 | 3 |

Viewed By 8477	Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Viewed By 3933	Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Viewed By 3724	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Viewed By 2747	KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications
Viewed By 2236	Predictors of steroid non-response and new approaches in severe alcoholic hepatitis

Cited By 43	Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017
Cited By 32	Application of transient elastography in nonalcoholic fatty liver disease
Cited By 30	Novel biomarkers for the management of chronic hepatitis B
Cited By 29	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Cited By 28	Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Search